Global Targeted Alpha-particle Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Targeted Alpha-particle Therapy market size was valued at US$ 1221 million in 2025 and is forecast to a readjusted size of US$ 3932 million by 2032 with a CAGR of 18.2% during review period.
Targeted Alpha-particle Therapy (TAT) is a novel radiopharmaceutical treatment technique that utilizes alpha-emitting radionuclides conjugated with targeting molecules to precisely kill tumor cells. The fundamental principle involves delivering alpha-emitting radionuclides—which possess potent cell-killing capabilities (such as Radium-223, Actinium-225, Bismuth-213, Lead-212, and Astatine-211)—to tumor tissues via antibodies, peptides, small-molecule ligands, or other biological targeting vectors. These radionuclides release high-energy alpha particles in the vicinity of cancer cells; the resulting radiation, characterized by a very short range and high Linear Energy Transfer (LET), directly disrupts the double-strand structure of cancer cell DNA, thereby inducing apoptosis or irreversible damage to the tumor cells. Compared to traditional beta-particle radiotherapy, alpha particles possess high energy and a short range of action (typically only tens of micrometers, equivalent to the diameter of a few cells), allowing for the destruction of tumor cells while minimizing radiation damage to surrounding healthy tissues.
TAT represents a significant development in the fields of precision nuclear medicine and radiopharmaceuticals; its core components include alpha-emitting radionuclides, targeting delivery molecules, and drug conjugation technology platforms. Specifically, the alpha radionuclide determines the therapeutic energy and half-life characteristics; the targeting molecule dictates the drug's ability to recognize tumor cells; and chelating agents and conjugation technologies influence radionuclide stability and in vivo distribution. Currently, this technology is primarily applied to the treatment of refractory cancers, including prostate cancer, neuroendocrine tumors, leukemia, ovarian cancer, and pancreatic cancer. Notably, Radium-223 dichloride is already used to treat bone-metastatic prostate cancer, while targeted radiopharmaceuticals based on radionuclides such as Actinium-225 and Lead-212 are becoming a focal point of clinical research.
From an industry chain perspective, the upstream sector primarily encompasses alpha radionuclide production, isotope separation and purification, nuclear reactor or accelerator facilities, and the development of chelating agents and targeting vectors. The midstream sector consists mainly of radiopharmaceutical R&D companies responsible for radionuclide labeling, drug preparation, quality control, and clinical development. The downstream sector includes hospital nuclear medicine departments, oncology treatment centers, and clinical application for patients. Due to challenges such as difficult production, complex supply chains, short half-lives, and stringent requirements for transport and storage, the number of enterprises and institutions worldwide capable of supplying alpha-emitting radionuclides at scale remains limited.
Looking ahead, the development of Targeted Alpha-particle Therapy will be driven by factors such as the growing demand for precision oncology, the accelerated R&D of innovative nuclear medicine drugs, and enhanced supply capabilities for radioactive isotopes. With continuous breakthroughs in production technologies for novel therapeutic radionuclides—such as Actinium-225 and Lead-212—alongside advancements in AI-assisted drug design, companion diagnostics, and personalized dosimetry, targeted alpha therapy is poised to emerge as a major cancer treatment modality following chemotherapy, immunotherapy, and beta-emitter therapy. This evolution will propel the radiopharmaceutical industry toward greater precision, efficiency, and personalization.
The core drivers of the Targeted Alpha-particle Therapy industry's growth stem from the rising global demand for cancer treatment and the deepening adoption of precision oncology concepts. As the global incidence of cancer rises—along with the number of patients suffering from advanced solid tumors, metastatic cancer, and refractory malignancies—traditional chemotherapy, immunotherapy, and beta-radionuclide therapies have shown limitations in efficacy or tolerability for certain patient populations. By leveraging the high linear energy transfer (LET) characteristics of alpha particles, targeted alpha-particle therapy induces DNA double-strand breaks in tumor cells over extremely short distances, achieving highly efficient cell killing while minimizing radiation exposure to surrounding healthy tissues; consequently, it demonstrates significant clinical value in treating prostate cancer, neuroendocrine tumors, hematologic malignancies, and various solid tumors.
Advancements in radiopharmaceutical R&D technologies and improved supply capabilities for key alpha-emitting radionuclides are propelling industry growth. In recent years, therapeutic alpha-emitters such as Actinium-225, Lead-212, Bismuth-213, and Astatine-211 have garnered widespread attention; continuous optimization of radionuclide production, separation and purification, radiolabeling, and chelator technologies has enhanced the feasibility of developing alpha-emitter-based drugs. Simultaneously, the development of targeting agents—including antibodies, peptides, and small-molecule ligands—along with novel delivery platforms, enables alpha-emitters to target tumor cells with greater precision and improves control over drug distribution within the body. With the maturation of nuclear medicine infrastructure and an increasing number of clinical trials, targeted alpha-particle therapy is transitioning from early-stage scientific research toward commercial application.
Furthermore, targeted alpha-particle therapy is poised to expand into a broader range of cancer types and evolve toward combination therapies and intelligent, data-driven approaches. Future R&D will shift from developing drugs for single indications to creating radiopharmaceutical platforms that cover a wider array of cancers, such as prostate, breast, pancreatic, and ovarian cancers, as well as gliomas. Additionally, alpha-emitter therapy is expected to integrate with immunotherapy, targeted therapy, and genetic testing technologies, enabling highly personalized treatment plans through patient screening based on molecular biomarkers and precision dosimetry. Developments in AI-assisted drug screening, image-guided dose assessment, and companion diagnostics will further enhance therapeutic outcomes and the efficiency of clinical application.
Report Scope
This report is a detailed and comprehensive analysis for global Targeted Alpha-particle Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Alpha-particle Therapy market size and forecasts, in consumption value ($ Million), 2021-2032
Global Targeted Alpha-particle Therapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted Alpha-particle Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted Alpha-particle Therapy market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Alpha-particle Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Alpha-particle Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, Fusion Pharmaceuticals(AstraZeneca), AlphaGen Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted Alpha-particle Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Actinium-225
Astatine-211
Lead-212
Bismuth-213
Others
Market segment by Targeted Carriers
Antibody-based α Therapy
Peptide Receptor Radionuclide Therapy
Small Molecule α Therapy
Nano-carrier α Therapy
Cell-based α Therapy
Market segment by Therapeutic Target
PSMA-targeted Alpha Therapy
SSTR-targeted Alpha Therapy
CD33/CD45-targeted Alpha Therapy
HER2-targeted Alpha Therapy
EGFR-targeted Alpha Therapy
Others
Market segment by Drug Delivery Method
Systemic Administration
Local Administration
Radioimmunotherapy
Combination Therapy Alpha Drugs
Market segment by Application
Immunotherapy
Peritoneal Carcinomas
Bone Metastases
Leukaemia
Melanomas
Solid Tumours
Market segment by players, this report covers
Bayer
Orano Med
Oncoinvent AS
Perspective Therapeutics
Ablaze Pharma
ARTBIO
Fusion Pharmaceuticals(AstraZeneca)
AlphaGen Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Targeted Alpha-particle Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted Alpha-particle Therapy, with revenue, gross margin, and global market share of Targeted Alpha-particle Therapy from 2021 to 2026.
Chapter 3, the Targeted Alpha-particle Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted Alpha-particle Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Alpha-particle Therapy.
Chapter 13, to describe Targeted Alpha-particle Therapy research findings and conclusion.